Evaluation of serum galectin-3 levels at Alzheimer patients by stages: a preliminary report.

Autor: Yazar T; Neurology, Zeytinburnu Surp Pirgıç Armenian Hospital, İstanbul, Turkey. tamer.yazar@yahoo.com.tr., Olgun Yazar H; Neurology, Taksim Training and Research Hospital, İstanbul, Turkey., Cihan M; Clinical Biochemist, Ordu University Training and Research Hospital, Ordu, Turkey.
Jazyk: angličtina
Zdroj: Acta neurologica Belgica [Acta Neurol Belg] 2021 Aug; Vol. 121 (4), pp. 949-954. Date of Electronic Publication: 2020 Aug 27.
DOI: 10.1007/s13760-020-01477-1
Abstrakt: Background and Aims: Neuroinflammation has a critic role in the pathophysiology of neurological diseases. The activation of microglia is the main actor in this process. The aim of this study to collect data on the role of microglial activation in the etiology, and the possible continuum at the stage of disease through the evaluation of serum galectin-3 levels in patients with Alzheimer's disease (AD).
Methods: This was a prospective and cross-sectional study conducted on patients who were diagnosed as having AD using the criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and stages determined with the scales of Clinical Dementia Rating (CDR) and Mini-Mental State Examination (MMSE) with healthy controls.
Results: In our study, we studied 118 people, 57 with AD and 61 healthy people as a control group. In the AD patient group, serum galectin-3 levels were higher compared with the control group (p = 0.003). There were no significant differences in either group in other collected parameters (p > 0.05). It was observed that in all patients with AD, parallel to the stage of the disease, serum galectin-3 levels, patience's age, and duration of disease were statically and significantly increased (p < 0.05).
Conclusion: In conclusion, serum galactin-3 levels may be associated with AD and maybe a potential biomarker for the identification of disease in the early stages. In future years, serum galectin-3 levels may become an important biomarker and therapeutic agent for chronic neurodegenerative diseases such as AD.
(© 2020. Belgian Neurological Society.)
Databáze: MEDLINE
Externí odkaz: